US FDA accepts supplemental new drug application for Jardiance for adults with chronic kidney disease
The supplemental New Drug Application is based on results from the landmark EMPA-KIDNEY phase III trial
The supplemental New Drug Application is based on results from the landmark EMPA-KIDNEY phase III trial
mRNA-1345 demonstrated vaccine efficacy of 83.7% against RSV lower respiratory tract disease, defined by 2 or more symptoms in older adults
Products offered on a not-for-profit basis to the 45 lower-income countries now include the full portfolio for which Pfizer has global rights.
Multilateral collaborations will serve to strengthen knowledge sharing to formulate framework for accessible, affordable, and quality healthcare
Following successful completion of full set of clinical studies of proposed rituximab biosimilar candidate DRL_RI, Dr. Reddy’s will now prepare to file in the United States, European Union and other regions
There is a great opportunity for utilizing traditional medical practices like Ayurveda in Value Based Healthcare
The goal is to bring oncology therapy closer to the communities by integrating all services such as chemotherapy and radiation centers
The AGE1.CR.pIX cell line is derived from primary cells of a duck embryo and was designed to comply with health authority guidelines
Valentas and Arnipin are indicated to reduce repeated hospitalization and the risk of cardiovascular death among adult patients with chronic mild to moderate heart failure
This donation will allow the continuation of the cycle of vaccination for children foreseen within the national immunization program carried out by the Ministry of Public Health of Cuba
Subscribe To Our Newsletter & Stay Updated